CK-102

CK-102 is an interleukin-1 (IL-1) inhibitor. CK-102 reduces mRNA synthesis. CK-102 does not inhibit DNA synthesis. CK-102 only slightly inhibits protein synthesis, or has no effect on it. CK-102 delays wound healing after ophthalmic surgery and prolongs the failure time of trabeculectomy fistulas. CK-102 inhibits lens protein-induced ocular inflammation at both early and late stages. CK-102 inhibits endotoxin-induced uveitis. CK-102 does not inhibit interleukin-1-induced uveitis. CK-102 can be used in research related to glaucoma filtration failure and uveitis^[1][2][3]. In Vitro:CK-102 (10-100 μg/mL; 24-72 h) inhibits proliferation of SIRC rabbit corneal fibroblast cells in a non-cytolytic manner, with viable cell counts remaining at or above initial levels while growing more slowly than controls across 10, 30, and 100 μg/mL concentrations at 24, 48, and 72 h^[1].
CK-102 (10-100 μg/mL; 24-72 h) produces limited, inconsistent inhibition of DNA synthesis, transient inhibition of RNA synthesis at 24 and 48 h, and variable effects on protein synthesis (with occasional reduction or increase) in SIRC rabbit corneal fibroblast cells across 10, 30, and 100 μg/mL concentrations at 24, 48, and 72 h^[1]. In Vivo:CK-102 (10 mg; subTenons injection; single dose; immediately after surgery) administered as a single 10 mg subTenons injection immediately after trabeculectomy statistically significantly prolongs the time to filtration fistula failure by 30% in Dutch Belted rabbits with no observed side effects^[2].
CK-102 (1%; topical; single instillation; 1 hour prior to lens protein challenge) significantly suppresses both early and late phases of lens protein-induced uveitis in Oryctolagus cuniculus, with comparable efficacy to Prednisolone (HY-17463)^[3].
CK-102 (10 mg/kg; i.p.; three times daily) significantly suppresses endotoxin-induced uveitis in rats, with greater potency than Prednisolone at an equivalent dose^[3].
CK-102 (10 mg/kg; i.p.; three times daily) does not suppress interleukin-1-induced uveitis in rats^[3].